IMPA1 Rabbit anti-Human, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA529008
PA5-29009 targets p53R2 in IHC (P) and WB applications and shows reactivity with Human and mouse samples. The PA5-29009 immunogen is recombit fragment corresponding to a region within amino acids 1 and 351 of Human p53R2.This gene encodes an enyzme that dephosphorylates myo-inositol monophosphate to generate free myo-inositol, a precursor of phosphatidylinositol, and is therefore an important modulator of intracellular signal transduction via the production of the second messengers myoinositol 1,4,5-trisphosphate and diacylglycerol. This enzyme can also use myo-inositol-1,3-diphosphate, myo-inositol-1,4-diphosphate, scyllo-inositol-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates. This enzyme shows magnesium-dependent phosphatase activity and is inhibited by therapeutic concentrations of lithium. Inhibition of inositol monophosphate hydroylosis and subsequent depletion of inositol for phosphatidylinositol synthesis may explain the anti-manic and anti-depressive effects of lithium administered to treat bipolar disorder. Alternative splicing results in multiple transcript variants encoding distinct isoforms. A pseudogene of this gene is also present on chromosome 8q21.13.
|Recombit fragment corresponding to a region within amino acids 1 and 277 of Human IMPA1|
|Antigen affinity chromatography|
|Immunohistochemistry (Paraffin), Western Blot|
|0.1M tris glycine with 20% glycerol and 0.01% thimerosal; pH 7|
|IMP, IMPA, IMP 1, IMPase 1, inositol monophosphatase 1, inositol-1(or 4)-monophosphatase 1, lithium-sensitive myo-inositol monophosphatase A1|
|-20° C, Avoid Freeze/Thaw Cycles|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok